Sometimes during the lifetime of a company significant shifts in priorities and resource allocation are made. I believe the ability to recognize the need for such changes and the wherewithal to carry … [Read more...] about DVAX Restructuring Surprise; Was A Sell-Off The Right Reaction?
One of the most heralded oncology conferences is the annual American Society of Clinical Oncologists (ASCO). This year, Chicago is hosting the annual conference, which is running from May 31st through … [Read more...] about ASCO Alert: Stay Ahead of the Updates
Novo Nordisk (NYSE: NVO) is a global healthcare company engaged in diabetes care, obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other … [Read more...] about Is Novo Nordisk Ready For Increased Biosimilar Competition?
Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
Leave a comment and click here to subscribe for MS article alerts and our newsletter! MRK Exercises Option For NGM Bio's Investigational Insulin Sensitizer-NGM313 January 3rd, 2019 MRK … [Read more...] about MS Morning Update
Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership